Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Author(s):
Bent, M.J. van den; Klein, M.; Smits, M.; Reijneveld, J.C.; French, P.J.; Clement, P.; Vos, F.Y.F. de; Wick, A.; Mulholland, P.J.; Taphoorn, M.J.B.; Lewis, J.; Weller, M.; Chinot, O.L.; Kros, J.M.; Heer, I. de; Verschuere, T.; Coens, C.; Golfinopoulos, V.; Gorlia, T.; Idbaih, A.
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-09-30
Language
English
Is part of
The Lancet Oncology (2018), Vol. 19, no. 9, p. 1170-1179
